ER-positive – Talk Bio

Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025

7 days ago talkbio0Tagged ER-positive, giredestrant, HER2-negative, Malignant neoplasm of breast, Oral SERD, Phase 3 trial, Progression-Free Survival, Roche (company), Selective Estrogen Receptor Down Regulator

Roche; SERD; giredestrant; breast cancer; ESMO 2025; progression-free survival; oral SERD; ER-positive; HER2-negative; phase 3 trial

Roche’s Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial

1 month ago talkbio0Tagged advanced breast cancer, Clinical Research, ER-positive, giredestrant, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, Phase 3 Clinical Trials, Progression-Free Survival, Roche (company)

Roche; oral SERD; giredestrant; progression-free survival; pivotal study; breast cancer; ER-positive; endocrine therapy; Phase III trial; advanced breast cancer

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

11 months ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)